• FAQ
  • Glossary
Fermer

FAQ

Why are animal models used when testing the safety of a new therapy?
What role do preclinical and clinical trials play in ensuring patient safety?
Why are some conditions more suitable for gene and cell therapies than others?
There is an approved treatment available for my condition - why can't I receive it?
How to look for approved medicines?
How are medicines developed and approved?

Voir toutes les FAQ

Fermer

Glossary

Accelerated assessment
Adeno-associated virus (AAV)
Adenovirus
Adult stem cells
Advanced Therapy Investigational Medicinal Product (ATIMP)
Advanced Therapy Medicinal Product (ATMP)
Advertising 
Antibody
Antigen
Base editors

Voir le glossaire complet

Retour à l'index du glossaire

Centralised authorisation procedure

Obligatory procedure at the European Union level for the approval of some medicines to be marketed in Europe. 

 

Read related content in the entries on  Standard Marketing Authorisation Pathway of the research pathways.

Retour en haut de page
Le contenu de cette page vous a-t-il été utile ? Envoyez-nous vos commentaires